GLP-1 Crackdown: What the FDA Really Means & Why Compounding Still Matters
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
GLP-1 Crackdown: What the FDA Really Means & Why Compounding Still Matters
-
Narrado por:
-
De:
Acerca de esta escucha
There’s been a lot of noise lately around semaglutide, tirzepatide, and other GLP-1 medications—especially as the FDA cracks down on certain compounded versions. But what’s really going on? And what should patients and providers know?
In this solo episode, I unpack the truth behind the headlines. We’ll clarify what GLP-1 medications actually are (hint: they’re not insulin), why they’re in such high demand, and how compounding pharmacies legally stepped in during national shortages. I’ll also break down the difference between 503A and 503B pharmacies and share how to spot quality in compounded meds.
Whether you’re a patient, provider, or pharmacy pro, this episode clears the fog around GLP-1s and gives you real tools to stay informed.
Todavía no hay opiniones